Comprehensive review on molnupiravir in COVID-19 : a novel promising antiviral to combat the pandemic
Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for the relevant articles regarding the pharmacokinetics, pharmacodynamics and clinical trials of molnupiravir in the management of COVID-19 is conducted. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Future microbiology - 17(2022) vom: 24. März, Seite 377-391 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khiali, Sajad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5CSZ8459RP |
|---|
| Anmerkungen: |
Date Completed 09.03.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fmb-2021-0252 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337312389 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337312389 | ||
| 003 | DE-627 | ||
| 005 | 20231225234129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fmb-2021-0252 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337312389 | ||
| 035 | |a (NLM)35199608 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khiali, Sajad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comprehensive review on molnupiravir in COVID-19 |b a novel promising antiviral to combat the pandemic |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for the relevant articles regarding the pharmacokinetics, pharmacodynamics and clinical trials of molnupiravir in the management of COVID-19 is conducted. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a MK-4482 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a direct-acting antivirals | |
| 650 | 4 | |a molnupiravir | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxylamines |2 NLM | |
| 650 | 7 | |a Cytidine |2 NLM | |
| 650 | 7 | |a 5CSZ8459RP |2 NLM | |
| 650 | 7 | |a molnupiravir |2 NLM | |
| 650 | 7 | |a YA84KI1VEW |2 NLM | |
| 700 | 1 | |a Khani, Elnaz |e verfasserin |4 aut | |
| 700 | 1 | |a B Rouy, Samineh |e verfasserin |4 aut | |
| 700 | 1 | |a Entezari-Maleki, Taher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future microbiology |d 2006 |g 17(2022) vom: 24. März, Seite 377-391 |w (DE-627)NLM171766504 |x 1746-0921 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g day:24 |g month:03 |g pages:377-391 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fmb-2021-0252 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |b 24 |c 03 |h 377-391 | ||